Eagles Matthew E, Nassiri Farshad, Badhiwala Jetan H, Suppiah Suganth, Almenawer Saleh A, Zadeh Gelareh, Aldape Kenneth D
Section of Neurosurgery, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada,
Ther Clin Risk Manag. 2018 Jul 26;14:1299-1313. doi: 10.2147/TCRM.S135865. eCollection 2018.
Glioblastoma (GBM) is the most common and fatal primary adult brain tumor. To date, various promising chemotherapeutic regimens have been trialed for use in GBM; however, temozolomide (TMZ) therapy remains the only US Food and Drug Administration-approved first-line chemotherapeutic option for newly diagnosed GBM. Despite maximal therapy with surgery and combined concurrent chemoradiation and adjuvant TMZ therapy, the median overall survival remains approximately 14 months. Given the failure of conventional chemotherapeutic strategies in GBM, there has been renewed interest in the role of immunotherapy in GBM. Dendritic cells are immune antigen-presenting cells that play a role in both the innate and adaptive immune system, thereby making them prime vehicles for immunotherapy via dendritic cell vaccinations (DCVs) in various cancers. There is great enthusiasm surrounding the use of DCVs for GBM with multiple ongoing trials. In this review, we comprehensively summarize the safety, efficacy, and quality of life results from 33 trials reporting on DCV for high-grade gliomas.
胶质母细胞瘤（GBM）是最常见且致命的原发性成人大脑肿瘤。迄今为止，已对多种有前景的化疗方案进行了GBM治疗试验；然而，替莫唑胺（TMZ）疗法仍是美国食品药品监督管理局批准的、用于新诊断GBM的唯一一线化疗选择。尽管采用手术以及同步放化疗和辅助TMZ治疗的综合疗法，但中位总生存期仍约为14个月。鉴于传统化疗策略在GBM治疗中失败，免疫疗法在GBM中的作用重新引起了人们的关注。树突状细胞是免疫抗原呈递细胞，在先天性和适应性免疫系统中均发挥作用，因此使其成为通过树突状细胞疫苗接种（DCV）对各种癌症进行免疫治疗的主要载体。围绕DCV用于GBM有多项正在进行的试验，人们对此充满热情。在本综述中，我们全面总结了33项关于DCV用于高级别胶质瘤的试验所报告的安全性、疗效和生活质量结果。
